Associated Papers
Inhibition Mechanism of Ketamine-Apatinib by CYP2C9 and 3A4: A Prediction of Possible Drug-Drug Interaction.
Zheng X et al.
Biopharmaceutics & Drug Disposition, 2025
The relationship between CYP2C9 gene polymorphisms and azilsartan metabolism in vitro.
Bao SS et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
A New Cloud-Native Tool for Pharmacogenetic Analysis.
Yuan DY et al.
Genes, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Enzymatic activity of 38 CYP2C9 genotypes on ibuprofen.
Yuan LJ et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association, 2023
Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects.
Zhang Q et al.
Frontiers in Endocrinology, 2023
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
Clinical significance of the series of CYP2C9*non3 variants, an unignorable predictor of warfarin sensitivity in Chinese population.
Wang D et al.
Frontiers in Cardiovascular Medicine, 2022
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Functional Assessment of 12 Rare Allelic CYP2C9 Variants Identified in a Population of 4773 Japanese Individuals.
Kumondai M et al.
Journal of Personalized Medicine, 2021
CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants.
Zhang L et al.
Clinical and Translational Science, 2020
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Metabolism of steroids by cytochrome P450 2C9 variants.
Uno T et al.
Biopharmaceutics & Drug Disposition, 2018
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
Daly AK et al.
Journal of Personalized Medicine, 2017
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.
Isvoran A et al.
Drug Discovery Today, 2017
Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants.
Hiratsuka M
Biological & Pharmaceutical Bulletin, 2016
In vitro and in vivo characterization of 13 CYP2C9 allelic variants found in Chinese Han population.
Hu GX et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2015
Warfarin dose requirements in a patient with the CYP2C9*14 allele.
Lee YM et al.
Pharmacogenomics, 2014
Functional characterization of 32 CYP2C9 allelic variants.
Niinuma Y et al.
The Pharmacogenomics Journal, 2014
CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database.
Dai DP et al.
The Pharmacogenomics Journal, 2014
Advances in molecular modeling of human cytochrome P450 polymorphism.
Martiny VY et al.
Journal of Molecular Biology, 2013
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
Zhou SF et al.
Toxicology, 2010
Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2010
Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?
Agúndez JA et al.
Expert Opinion on Drug Metabolism & Toxicology, 2009
Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes.
Wen MS et al.
Clinical Pharmacology and Therapeutics, 2008
Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors.
D'Andrea G et al.
Blood Reviews, 2008
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
Yin T et al.
Thrombosis Research, 2007
Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese.
Maekawa K et al.
Pharmacogenetics and Genomics, 2006
Contribution of CYP2C9 to variability in vitamin K antagonist metabolism.
Daly AK et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians.
DeLozier TC et al.
The Journal of Pharmacology and Experimental Therapeutics, 2005
A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.
Yuan HY et al.
Human Molecular Genetics, 2005
Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose.
Zhao F et al.
Clinical Pharmacology and Therapeutics, 2004